Blood Tests Could Spot Brain Injury Patients at Risk for Later Seizures

Doctors have long struggled to predict which patients will develop seizures long after a head injury. A team of researchers recently tackled this problem by tracking specific substances in the blood that might reveal hidden damage inside the brain. Their findings suggest that a simple blood test could eventually help identify high-risk patients before seizures ever appear.

The study followed 126 individuals who had experienced moderate traumatic brain injury. Researchers monitored six different biomarkers in their blood over a full year. These biomarkers included markers of inflammation, immune system activity in the brain, and actual nerve cell damage. The goal was to see whether patterns in these substances could forecast which patients would develop late-onset seizures or post-traumatic epilepsy.

Of the original group, 13 patients eventually experienced late seizures or related conditions, while 113 did not. The contrast between these two groups was striking. Patients who went on to develop seizures showed consistently elevated levels of inflammatory markers and indicators of ongoing brain tissue injury across every testing interval. Certain markers stayed high from the very first days after injury all the way through three months later.

The research team identified specific cutoff values that signaled increased risk. For instance, interleukin-6 levels at or above 10 picograms per milliliter proved significant. Similarly, tumor necrosis factor-alpha exceeding 7.5 pg/mL and neurofilament light chain at or above 35 pg/mL were flagged as warning signs. By combining just three of these biomarkers, the researchers created what they called a BioIndex score.

Patients whose BioIndex reached two or higher faced a substantially higher chance of experiencing seizures within the following year. This composite approach proved more practical than examining each marker individually. The researchers believe this tool could eventually help doctors customize follow-up care for brain injury survivors, ensuring those at greatest risk receive appropriate monitoring and preventive strategies.

The implications extend beyond simple prediction. Early identification of at-risk patients could opens doors to research into preventive treatments. Scientists could test interventions in precisely the population most likely to benefit. For patients and families, knowing the risk level might reduce anxiety and guide lifestyle adjustments during recovery. While more research remains necessary before widespread clinical use, this work represents a meaningful step toward personalized care for traumatic brain injury survivors.